TSHA stock falls as FDA seeks additional dosing for CNS disorder candidate (NASDAQ:TSHA)
Taysha Gene Therapies (TSHA) fell post-market Tuesday after as FDA recommended dosing more patients to support a marketing application for TSHA-120 in giant axonal neuropathy ((GAN)).
Source: seekingalpha.com